NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis

$0.65
-0.03 (-4.42 %)
(As of 06/19/2019 03:40 AM ET)
Today's Range
$0.6236
Now: $0.6484
$0.68
50-Day Range
$0.61
MA: $1.17
$1.55
52-Week Range
$0.61
Now: $0.6484
$3.70
Volume425,132 shs
Average Volume661,031 shs
Market Capitalization$48.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
CUSIPN/A
Phone604-558-6536

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.27 per share

Profitability

Net Income$-53,330,000.00

Miscellaneous

Employees79
Market Cap$48.43 million
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) issued its earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.04. View Sierra Oncology's Earnings History.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Sierra Oncology.

What is the consensus analysts' recommendation for Sierra Oncology?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology.

Has Sierra Oncology been receiving favorable news coverage?

Headlines about SRRA stock have trended very negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sierra Oncology earned a news impact score of -3.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Sierra Oncology.

Who are some of Sierra Oncology's key competitors?

What other stocks do shareholders of Sierra Oncology own?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 62)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50)

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (0.65%), Spark Investment Management LLC (0.53%), Algert Global LLC (0.11%), Connor Clark & Lunn Investment Management Ltd. (0.05%), Virtu Financial LLC (0.03%) and Brookstone Capital Management (0.02%). View Institutional Ownership Trends for Sierra Oncology.

Which institutional investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Spark Investment Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Sierra Oncology.

Which institutional investors are buying Sierra Oncology stock?

SRRA stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Virtu Financial LLC and Brookstone Capital Management. View Insider Buying and Selling for Sierra Oncology.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $0.6484.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $48.43 million. The biotechnology company earns $-53,330,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sierra Oncology employs 79 workers across the globe.View Additional Information About Sierra Oncology.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is http://www.sierraoncology.com/.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 - 885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]


MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel